Menopause represents one of the most significant physiological transitions impacting skeletal health. Although declining estrogen is widely recognized as a hallmark of menopause, its profound effects on bone remodeling are often underappreciated until bone loss has already occurred. Osteoporosis affects millions of women worldwide and is responsible for increased fracture risk, loss of independence, disability and mortality.  

Understanding the relationship between menopause and osteoporosis allows healthcare providers to identify patients at highest risk while educating women about strategies to preserve bone health throughout the menopausal transition and beyond. 

What is Osteoporosis? 

Let’s refresh our minds on what osteoporosis is: it’s a systemic skeletal condition characterized by reduced bone strength that predisposes individuals to increased risk of fractures. Bone strength is determined by both bone mineral density (BMD) and bone quality, including the architecture and structural integrity of bone.  

What does “bone density” mean? This refers to the amount of minerals, primarily calcium and phosphorus, contained within bone tissue. It is commonly measured using dual-energy X-ray absorptiometry (DEXA), which remains the gold standard for diagnosing osteoporosis. 

DEXA scans provide a measurement called a T-score, which reflects a patient’s BMD compared to the average BMD of a healthy, young adult. Below are T-score reference ranges which correspond to one’s level of bone health:  

• Normal bone density: T-score ≥ -1.0 
• Osteopenia: T-score between -1.0 and -2.5 
• Osteoporosis: T-score ≤ -2.5 

Understanding osteopenia vs osteoporosis is important. Osteopenia is lower-than-normal bone density but is not yet severe enough to meet criteria for osteoporosis. An osteopenia diagnosis represents a critical opportunity for bone health intervention before progression to osteoporosis.  

Why Does Menopause Increase Osteoporosis Risk? 

Many people tend to think of bone as a static anatomical structure that doesn’t really change, but bones are metabolically active tissue that continuously undergoes remodeling through coordinated actions of osteoclasts, which resorb bone, and osteoblasts, which form new bone. 

Estrogen plays a central role in maintaining this balance. It suppresses osteoclast activity, supports osteoblast survival, and helps regulate inflammatory cytokines involved in bone remodeling. 

As ovarian estrogen production declines during menopause, bone resorption accelerates while bone formation cannot fully compensate. Women may lose approximately 10-20% of their bone mass during the first five to seven years after menopause, making this one of the most rapid periods of skeletal loss across the lifespan. 

Estrogen and Bone Density: Does Estrogen Help with Bone Density? 

Estrogen is one of the most important regulators of bone metabolism. Research consistently demonstrates that estrogen deficiency increases osteoclast activity, resulting in greater bone breakdown. Estrogen also influences calcium absorption, vitamin D metabolism, and inflammatory signaling pathways that contribute to skeletal integrity. 

Because of these mechanisms, hormone therapy for osteoporosis prevention has been extensively studied. Menopausal hormone therapy (MHT) is FDA approved for the prevention of osteoporosis in postmenopausal women. The Menopause Society and other professional organizations recognize MHT as an effective option for preventing bone loss and reducing fracture risk in appropriately selected women, particularly those younger than 60 or within 10 years of menopause onset who also have bothersome vasomotor symptoms and no contraindications for hormone therapy. 

However, hormone therapy should not be initiated solely for osteoporosis treatment in women whose only concern is fracture prevention. Clinical decision-making should incorporate overall cardiovascular, breast cancer, thromboembolic, and individual patient risk profiles. 

What Causes Osteoporosis Beyond Menopause? 

Although estrogen deficiency is the primary driver of postmenopausal osteoporosis, multiple factors contribute to declining bone health: 

• Increasing age 
• Female sex 
• Family history of osteoporosis 
• Low body weight  
• Smoking, excessive alcohol intake 
• Physical inactivity 
• Vitamin D deficiency, low calcium intake 
• Long-term glucocorticoid therapy 
• Hyperthyroidism, hyperparathyroidism 
• Malabsorption disorders 
• Rheumatoid arthritis 
• Chronic kidney disease 
• Type 1 diabetes 
• Certain cancer therapies 

Many women accumulate several of these risk factors, highlighting the importance of comprehensive assessment rather than attributing bone loss solely to menopause. 

Osteoporosis Symptoms 

One of the greatest challenges in osteoporosis management is that osteoporosis symptoms are frequently absent until a fracture occurs. Many patients feel healthy despite significant reductions in bone density. As a result, osteoporosis is often discovered only after a low-trauma fracture occurs.  

When symptoms do develop, they may include: 

• Loss of height 
• Chronic back pain from vertebral compression fractures 
• Fragility fractures after minimal trauma 
• Progressive kyphosis (rounding of the upper back) 

This relatively quiet progression reinforces the importance of routine screening in at-risk women rather than waiting for symptoms to appear. 

Screening for Osteoporosis in Menopausal Women 

Professional organizations recommend bone mineral density testing using DEXA for all women aged 65 years and older, as well as younger postmenopausal women whose fracture risk is elevated based on risk factors. 

Risk assessment tools such as FRAX® can further estimate an individual's 10-year probability of major osteoporotic and hip fractures by incorporating bone density alongside other clinical variables. 

Laboratory evaluation may also be appropriate to investigate secondary causes of osteoporosis, particularly in women with unexpectedly severe bone loss or fractures occurring at a younger age. 

How to Prevent Osteoporosis 

Prevention of osteoporosis requires a comprehensive approach that addresses both lifestyle and medical risk factors: 

Prioritize Resistance and Weight-Bearing Exercise 

Mechanical loading stimulates bone formation. Resistance training, impact exercise, walking, stair climbing, and balance training all contribute to maintaining strength while reducing fall risk. Some women may benefit from a physical therapy referral for exercise support initially if significantly deconditioned. 

Optimize Calcium, Vitamin D, and Other Nutrients 

Adequate dietary calcium remains the preferred approach whenever possible with supplementation used when dietary intake is insufficient. Calcium supplement recommendations vary depending on age, bone health, country, and other factors. For personalized guidance, consult your healthcare provider.  

Vitamin D supports calcium absorption and bone mineralization. Serum vitamin D concentrations may be assessed in women at risk for deficiency. If the patient is deficient, optimize vitamin D levels through supplementation.  

Maintain Adequate Protein Intake 

Protein provides essential building blocks for bone matrix and muscle mass. Preserving muscle strength is particularly important because falls represent a major contributor to fracture risk. 

Avoid Tobacco and Limit Alcohol 

Smoking accelerates bone loss and increases fracture risk. Similarly, excessive alcohol intake negatively impacts bone health and increases fall risk. 

Fall Prevention 

Improving vision, reviewing medications that affect balance, optimizing home safety, and balance exercises can substantially reduce fracture risk independent of bone density. Yoga and tai chi can be great options for improving balance.  

How to Improve Bone Density 

How can we improve bone density once osteopenia or osteoporosis is diagnosed? A combination of several interventions typically yields the best outcomes: 

• Progressive resistance exercise 
• Regular weight-bearing physical activity 
• Adequate calcium intake, vitamin D optimization 
• Smoking cessation, limiting alcohol 
• Treating underlying endocrine or metabolic disorders 
• Pharmacologic therapy when indicated 

Medications including bisphosphonates, zoledronic acid, denosumab, selective estrogen receptor modulators (SERMs), menopausal hormone therapy, and anabolic agents each have specific indications depending on fracture risk and patient medical history.  

Where Does Hormone Testing Fit? 

As more women seek individualized approaches to menopause care, many are curious whether hormone testing like DUTCH can provide insight into bone health. 

Current evidence-based osteoporosis guidelines do not recommend hormone testing as a primary method for diagnosing osteoporosis, predicting fracture risk, or determining the need for osteoporosis treatment. These decisions should continue to rely on clinical history, fracture risk assessment, bone mineral density testing (DEXA), and established screening guidelines. 

However, hormone testing may offer valuable supplemental information in selected clinical settings. Tests such as DUTCH not only evaluate levels of sex hormones, but also patterns of estrogen metabolism, androgen metabolites, adrenal hormones, cortisol rhythms, and organic acids that may contribute to a more comprehensive picture endocrine health. 

Because estrogen plays a central role in maintaining bone remodeling, understanding an individual's hormonal milieu may help clinicians contextualize symptoms, evaluate the timing and progression of menopause, and guide individualized conversations about interventions like menopausal hormone therapy when clinically appropriate.  

As aforementioned, there are numerous markers on DUTCH besides estradiol that can provide additional bone health insights. Some examples include:  

• Total DHEA: DHEA stimulates bone formation and inhibits breakdown. Low levels of DHEA-S are associated with lower bone density and increased fracture risk  
• Free Testosterone: Low free testosterone is associated with lower BMD 
• 5a-androstanediol: Lower 5a-reduced metabolites may reflect impaired bone androgen action, including in bone  
• Diurnal cortisol pattern in urine or saliva: Elevated baseline and midnight salivary cortisol is inversely associated with lower BMD, and a flattened or elevated diurnal cortisol curve is associated with lower bone mass 
• Methylmalonic acid (MMA): This directly stimulates bone breakdown in a dose-dependent manner. Elevated MMA results from B-12 deficiency, so B-12 support may reduce bone breakdown if MMA is high. 
• And more!  

When used thoughtfully alongside evidence-based screening recommendations, tools like DUTCH can provide complementary information that support individualized patient care. 

A Proactive Approach to Bone Health 

Postmenopausal osteoporosis represents one of the most common chronic conditions affecting aging women, yet it remains highly amenable to prevention and early intervention. By integrating current clinical guidelines with personalized patient care, healthcare providers can help women maintain skeletal health well beyond menopause and optimize overall wellness.  

References 

1. The North American Menopause Society. The Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9): 973-997. 
2. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract. 2020;26(Suppl 1):1-46. 
3. Aibar-Almazán A, Voltes-Martínez A, Castellote-Caballero Y, Afanador-Restrepo DF, Carcelén-Fraile MDC, López-Ruiz E. Current Status of the Diagnosis and Management of Osteoporosis. Int J Mol Sci. 2022;23(16):9465. Published 2022 Aug 21. doi:10.3390/ijms23169465 
4. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-2381. 
5. Kanis JA, Harvey NC, Johansson H, et al. FRAX and fracture prediction without bone mineral density. Climacteric. 2015;18(Suppl 2):2-9. 
6. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. 
7. Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline update. J Clin Endocrinol Metab. 2020;105(3):587-594. 
8. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. 
9. Zhou S, Glowacki J. Dehydroepiandrosterone and Bone. Vitam Horm. 2018;108:251-271. doi:10.1016/bs.vh.2018.01.005 
10. Yokomoto-Umakoshi M, Umakoshi H, Ogawa Y. Imbalances in adrenal hormones and their effects on bone metabolism. Endocr J. 2025;72(12):1287-1297. doi:10.1507/endocrj.EJ25-0117 
11. Vaes BL, Lute C, Blom HJ, et al. Vitamin B(12) deficiency stimulates osteoclastogenesis via increased homocysteine and methylmalonic acid. Calcif Tissue Int. 2009;84(5):413-422. doi:10.1007/s00223-009-9244-8